DiaSorin stock gains 4.4 percent as it leads the FTSE MIB

Published on 09/19/2026 at 11:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin stock rose 4.4 percent over the week to September 18, 2026, topping Italy’s FTSE MIB index amid sector strength. The shares remain down about 1 percent year on year, highlighting a mixed longer term picture for investors.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin stock (ISIN IT0003497168) advanced 4.4 percent over the trading week ending September 18, 2026, making the Italian diagnostics specialist the best-performing component of the FTSE MIB index in that period.

DiaSorin tops Milan’s blue-chip index

According to MarketScreener on September 18, 2026, DiaSorin was the standout stock on the FTSE MIB, gaining 4.4 percent over the week while the index itself fell 1.8 percent.

The same overview notes that over the past 30 days DiaSorin shares are up 4.5 percent, but the year-on-year performance remains down 1.0 percent, underlining that the recent rebound has not yet fully erased earlier weakness.

Sector context and valuations

A sector snapshot from ChartMill dated September 18, 2026, lists DiaSorin under its Borsa Italiana symbol DIA.MI with an indicated market capitalization of EUR 3.73 billion and a price-to-earnings ratio of 20.13.

In the same health care sector table, DiaSorin shows a one-day performance of minus 1.04 percent, a one-month gain of 10.15 percent, a three-month decline of 10.14 percent and a one-year drop of 33.34 percent, illustrating that the strong recent week sits within a still challenging twelve-month trajectory.

Stock price level and investor view

The weekly gain of 4.4 percent against a 1.8 percent decline in the FTSE MIB means DiaSorin outperformed its home market by 6.2 percentage points for the week ending September 18, 2026, a move that may draw renewed attention from investors focused on European health care names.

With a market capitalization around EUR 3.73 billion and a price-to-earnings ratio of 20.13 as presented in the sector overview on September 18, 2026, DiaSorin’s valuation sits in a mid-range for established diagnostics companies, leaving room for fundamentals and future guidance to determine whether the recent rebound can be sustained.

DiaSorin stock price snapshot

Per the sector data as of September 18, 2026, DiaSorin stock on Borsa Italiana (ticker DIA.MI) is classified within the European health care group with an average daily trading volume of about 321,230 shares, providing reasonable liquidity for investors.